Literature DB >> 10818544

Leukoaraiosis at presentation and disease progression during follow-up in histologically confirmed cases of dementia.

R Clarke1, C Joachim, M Esiri, J Morris, H Bungay, A Molyneux, M Budge, C Frost, E King, L Barnetson, A D Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10818544     DOI： 10.1111/j.1749-6632.2000.tb06405.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  4 in total

Review 1.  Pathomechanism of leukoaraiosis: a molecular bridge between the genetic, biochemical, and clinical processes (a mitochondrial hypothesis).

Authors:  Zoltán Szolnoki
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

2.  Evaluation of the MTHFR A1298C variant in leukoaraiosis.

Authors:  Zoltan Szolnoki; Istvan Szaniszlo; Marta Szekeres; Krisztina Hitri; Andras Kondacs; Yvette Mandi; Erika Nedo; Ferenc Somogyvari
Journal:  J Mol Neurosci       Date:  2011-08-16       Impact factor: 3.444

3.  The combination of homozygous MTHFR 677T and angiotensin II type-1 receptor 1166C variants confers the risk of small-vessel-associated ischemic stroke.

Authors:  Zoltan Szolnoki; Anita Maasz; Lili Magyari; Katalin Horvatovich; Bernadett Farago; Ferenc Somogyvari; Andras Kondacs; Mihaly Szabo; Anita Bodor; Ferenc Hadarits; Bela Melegh
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

4.  Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion).

Authors:  Christopher M Reid; Elsdon Storey; Tien Y Wong; Robyn Woods; Andrew Tonkin; Jie Jin Wang; Anthony Kam; Andrew Janke; Rowan Essex; Walter P Abhayaratna; Marc M Budge
Journal:  BMC Neurol       Date:  2012-02-08       Impact factor: 2.474
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.